Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Recommendation of “Hold” by Brokerages

Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus recommendation of “Hold” from the eight research firms that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $20.40.

A number of research analysts have commented on the stock. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 15th. Finally, Wells Fargo & Company cut their price target on shares of Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Thursday, March 5th.

Keros Therapeutics Stock Up 0.4%

Shares of KROS opened at $11.23 on Wednesday. The stock has a market cap of $222.24 million, a price-to-earnings ratio of -3.73 and a beta of 0.95. Keros Therapeutics has a 12 month low of $9.79 and a 12 month high of $22.55. The company has a 50-day moving average price of $11.37 and a two-hundred day moving average price of $15.50.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($1.21) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.19). The business had revenue of $0.37 million for the quarter, compared to the consensus estimate of $1.93 million. Keros Therapeutics had a negative return on equity of 17.04% and a negative net margin of 256.60%. Equities research analysts expect that Keros Therapeutics will post -5.62 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Western Standard LLC lifted its stake in Keros Therapeutics by 42.7% during the third quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock worth $34,644,000 after purchasing an additional 654,989 shares during the period. Renaissance Technologies LLC increased its holdings in shares of Keros Therapeutics by 282.5% during the fourth quarter. Renaissance Technologies LLC now owns 591,686 shares of the company’s stock worth $12,047,000 after buying an additional 436,986 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in shares of Keros Therapeutics during the second quarter worth approximately $4,251,000. Caption Management LLC increased its holdings in shares of Keros Therapeutics by 114.1% during the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock worth $482,000 after buying an additional 291,997 shares in the last quarter. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Keros Therapeutics by 683.7% during the third quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock worth $4,795,000 after buying an additional 264,445 shares in the last quarter. Institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.